Anti-Human CD195 (CCR5) - Purified In vivo PLATINUM Functional Grade

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Rat

Immunogen

CHO cells transfected with full-length human CD195 (CCR5).

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

2-8°C

RRID

AB_2893834

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for this CD195 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

ICC

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone HEK/1/85a/7a recognizes an epitope on human CCR5.

Antigen Distribution

CCR5 is expressed on memory T cells, macrophages, and immature dendritic cells (DCs).

Background

CCR5 antibody, HEK/1/85a/7a, recognizes C-C chemokine receptor type 5 (CCR5), also known as CD195, CC-CKR-5, CHEMR13, and HIV-1 fusion coreceptor. CCR5 is a 45 kDa seven-transmembrane G-protein-coupled receptor (GPCR). CCR5 is expressed on a subset of memory T cells, macrophages, and immature dendritic cells (DCs) and is upregulated by proinflammatory cytokines^{1, 2}. CCR5 binds to inflammatory CC-chemokines, including CCL3 (macrophage inflammatory protein (MIP)-1α), CCL4 (MIP-1β), and RANTES, which increases intracellular calcium levels and results in cytoskeletal rearrangement and chemotactic cell migration³. CCR5 is also the coreceptor for HIV-1 following binding of viral gp120 to CD4^4-7. The levels of CCR5 on cells influence the rate of entry of HIV-1, and patients with lower levels of CCR5 exhibit immunity against infection⁸. CCR5 also contributes to other human diseases, including type I diabetes⁹ and cancer¹⁰.

Antigen Details

Protein

CD195

PubMed

CD195

NCBI Gene Bank ID

1234

References & Citations

1. Mackay CR., et al. (1997) Proc Natl Acad Sci. 94(5):1925-30
2. Doms RW., et al. (1999) Proc Natl Acad Sci. 96(9):5215-5220
3. Parmentier M., et al. (1996) Biochemistry. 35(11):3362-7
4. Berger EA., et al. (1996) Science. 272(5270):1955-8
5. Sodroski J., et al. (1996) Cell. 1996 85(7):1135-48
6. Doms RW., et al. (1996) Cell. 85(7):1149-58
7. Paxton WA., et al. (1996) Nature. 381(6584):667-73
8. Sheppard HW., et al. (1997) Nat Med. 3(10):1160-2
9. Delovitch TL., et al. (2000) J Immunol. 165(2):1102-10
10. Casagrande N., et al. (2020) Cancers (Basel). 12(7):1765

Technical Protocols